OncoSynergy Treats First Patient in Clinical Trial of Recurrent Glioblastoma

OncoSynergy, Inc. launched the company’s First-in-Human Phase 1 clinical trial evaluating a treatment of recurrent glioblastoma. Today they announced the first patient has been treated in this trial using OS2966, a first-in-class immunotherapy, and the …